Sign up Australia
Proactive Investors - Run By Investors For Investors

Abcam forecasts double digit revenue growth for full-year as it sees product growth across the board

The AIM-listed antibody supplier said it expected revenue for the full year to grow by 10.7% in constant currency, with catalogue growth of “over” 10%
Antibodies
Revenue from custom products and licensing also grew by 18% during the year

Abcam PLC (LON:ABC) said it expects double-digit growth in its full-year results following strong income growth across all of its product categories.

The AIM-listed antibody supplier said it expects revenue for the full year to grow by 10.7% in constant currency, with catalogue growth of “over” 10% underpinning the rise after all product categories continued to grow ahead of its market.

READ: Abcam raises revenue guidance after Roche deal

The firm added that revenue from custom products and licensing, which accounted for around 7% of total revenue, also grew by 18% during the year.

Abcam also said it expected margins to be in line with the previous year's figure of 70.1%, while margins for adjusted earnings before interest, taxes, depreciation and amortisation were forecast to be in line with expectations.

In a note to clients, analysts at City broker Numis upped their target price for the firm to 1,380p from 1,316p, citing that the strong growth forecasts could “indicate the emergence of a new fourth double-digit growth engine in the business”.

In lunchtime trading Thursday, Abcam shares were down 4.8% at 1,322p.

View full ABC profile View Profile

Abcam Timeline

Newswire
January 10 2017

Related Articles

1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use